CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces
"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.
Obesity and Hypertension: Addressing Misconceptions in Clinical Practice
Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.
ACG Updates Guidelines for Eosinophilic Esophagitis: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves Lilly’s Mirikizumab-mrkz for Crohn’s Disease
Marketed as Omvoh, the therapy is already approved as a first-in-class treatment for moderately to severely active ulcerative colitis.
Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist
Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.
USPSTF Issues Final Recommendations on Osteoporosis Screening to Prevent Fractures
The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.
GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management
More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.
Elinzanetant VMS update: As Positive Results Pile Up, Bayer Readies for Menopause Treatment’s Future
FDA action date set for July 26, 2025.
Higher Daily Step Count Linked to Lower Risk for Depression: Daily Dose
The Future of Migraine Care: 3 Wishes for Patients from Leading Neurologist and Researcher Peter McAllister, MD
Peter McAllister, MD,
Annual Incidence of Dementia in US Will Double by 2060, Reaching 1 Million Cases
Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.
Early Hypertensive Screening in Patients with Obesity: Expert Perspective
Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.
Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial
A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.
Neurotoxins, Biomarkers, and Migraine Advocacy: One Neurologist's Thoughts on Focus in 2025
Neurologist and clinical investigator Peter McAllister, MD, is eager to make progress in research on diagnosis and treatment and to hear more patient voices.
The FDA Accepts Eisai BLA for Lecanemab Subcutaneous Maintenance Dosing in Adults with Alzheimer Disease
Weekly SC injection of lecanemab is expected to maintain clinical and biomarker benefits reached during the IV initiation phase. The PDUFA date is Aug 31, 2025.
Neffy Update: FDA to Review 1 mg Version in First Quarter 2025, for Young Children with Type 1 Allergic Reactions
If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.
CRC Screening Expansion Strains Community Health Centers: Daily Dose
New Long-Term Data Suggest Continued Blarcamesine Efficacy in Alzheimer Disease Up to 4 Years
Blarcamesine significantly slowed progression of both cognitive and functional decline, with treatment initiated earlier in disease process more effective than that initiated later.
Phase 1b Trial of Oligomer-Targeting Agent PMN310 for Alzheimer Disease Gets Underway
The study will assess the safety, tolerability, and pharmacokinetics of PMN310 in individuals with mild cognitive impairment or early-stage AD.
Vertex on the Verge of Breakthrough for Nonopioid Pain Management as NOPAIN Act Takes Effect
Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.
